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Summary Etoposide phosphate is a water-soluble prodrug of etoposide. The plasma pharmacokinetics of etoposide following oral
administration of etoposide phosphate or oral etoposide were compared. Seventeen patients with solid tumours were enrolled to receive oral
etoposide phosphate 125 mg m-2 on days 1-5 every 3 weeks, with escalation to 175 mg m-2 from course 3 when possible. Patients were
randomized to receive oral etoposide phosphate or oral etoposide on day 1 of course 1 and the alternative compound on day 1 of course 2.
Fifteen patients received two or more courses and were evaluable for pharmacokinetic comparisons. The median AUCinf (area under the
concentration vs time curve from zero to infinity) of etoposide was 77.7 mg 1-1 h after etoposide phosphate (95% Cl 61.3-100.5) and
62.0 mg 1-1 h after oral etoposide (95% Cl 52.2-76.9). The difference in favour of etoposide phosphate was borderline significant: median
9.9 mg 1-1 h (95% Cl 0.1-32.8 mg 1-1 h; P= 0.05). However, the inter-patient variability of etoposide AUCinf was not improved (coefficients of
variation 42.3% and 48.4%). Etoposide phosphate was undetectable in plasma after oral administration. Toxicities of oral etoposide
phosphate were not different from those known for etoposide. In conclusion, oral etoposide phosphate does not offer a clinically relevant
benefit over oral etoposide.
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Etoposide, a podophyllotoxin derivative, is incorporated in stan-
dard chemotherapy for treatment ofsmall-cell lung cancer (SCLC)
and germ cell tumours, as well as in second-line treatment for
haematological and many other malignancies (Hainsworth and
Greco, 1995). Activity is improved considerably when the dose is
divided over several days, and therefore oral administration is
attractive (Slevin et al, 1989a). It has been shown that oral etopo-
side monotherapy, usually with the dose divided over 5 days or
longer periods, is an effective treatment in patients with SCLC and
refractory malignant lymphomas (Hainsworth and Greco, 1995).
In small studies, prolonged oral etoposide treatment showed
remarkable activity in relapsed or refractory breast and ovarian
cancers (response rates up to 35% and 25% respectively) (Hoskins
and Swenerton, 1994; Martin et al, 1994). Patient convenience is
an important additional reason for choosing the oral route.
However, pharmacokinetic studies have shown that oral etoposide
also has disadvantages. Bioavailability is incomplete, probably
decreasing with dose, and is reported to be below 50% for doses
above 200 mg. Bioavailability shows wide inter- and intra-patient
variability (Hande et al, 1993; Harvey et al, 1985; Slevin et al,
1989b). The consequences are considerable risks of underdosing
and unpredictable toxicity.
The water-soluble prodrug etoposide phosphate was synthe-
sized because use of intravenous etoposide administration is
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associated with problems due to precipitation that require addition
of solvents and dilution in large volumes. It is a derivative of
etoposide characterized by a phosphate group in position 4' ofthe
E-ring ofthe etoposide molecule (Saulnier et al, 1994). Etoposide
phosphate is rapidly converted to etoposide after intravenous
administration, presumably by plasma phosphatases, resulting in
pharmacokinetic equivalence with etoposide (Budman et al, 1994;
Fields et al, 1995; Sessa et al, 1995). Recently published studies
have shown that etoposide phosphate administered intravenously
has efficacy and toxicity similar to molar-equivalent etoposide
doses (Budman et al, 1994; Fields et al, 1995; Hainsworth et al,
1995). Because of the better water solubility, oral administration
of etoposide phosphate could be expected to result in improved
and less variable bioavailability of etoposide compared with oral
etoposide. The possibility oforal etoposide phosphate administra-
tion up to a daily dose of 125-175 mg m-2 for 5 days was demon-
strated in recent clinical phase I studies (Sessa et al, 1995; Chabot
et al, 1996). The aims of the present study were to compare the
plasma pharmacokinetics of etoposide following oral administra-
tion ofetoposide phosphate and etoposide in the same patients and
to study further the safety of oral etoposide phosphate. Seventeen




Patients aged 18-75 years with histologically proven solid malig-
nancies, either no longer amenable to established forms of treat-
ment or potentially responsive to etoposide, and a performance
status of 0 or 1 on the WHO scale as well as a life expectancy of
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> 3 months were eligible for this study. Patients with cerebral or
leptomeningeal metastases were excluded. Patients were required
to have a leucocyte count . 4.0 x 103 p1l-, a platelet count
2 100 x 103 p-', and adequate liver and kidney function (bilirubin
<25 ,umol 1-, transaminases within twice the upper normal limit
unless related to liver metastases; serum creatinine < 120,umol 1-1).
Patients who received chemo-, immuno- or radiotherapy within
the previous 4 weeks or nitrosureas, mitomycin C or extensive
radiotherapy within the previous 6 weeks were not eligible. Also
patients with malabsorption disorders or gastric resections were
excluded. The protocol was approved by the Medical Ethics
Committee of the University Hospital Groningen and all patients
gave written informed consent.
Pretreatment evaluation included a complete history and physical
examination, laboratory evaluation with a complete blood count and
differential, blood urea nitrogen and creatinine, serum electrolytes,
aspartate transaminase, alanine transaminase, gamma-glutamyl
transpeptidase, alkaline phosphatase, bilirubin, glucose, total protein
and albumin. These evaluations were repeated before each course
and after treatment discontinuation. Pretreatment evaluation also
included prothrombin time and partial thromboplastin time, electro-
cardiogram and chestradiograph. Creatinine clearance was estimated
using Cockroft and Gault's formula (Cockroft and Gault, 1976).
Dose schedule and drug administration
The patients were randomized to receive either etoposide or etopo-
side phosphate orally on day 1 of the first course and the alterna-
tive compound on day 1 of the second course. On days 2-5 of the
first two courses and from course 3 onwards, patients always
received oral etoposide phosphate. The dose of etoposide and
etoposide phosphate was 125 mg m-2 once daily for 5 consecutive
days, based on the maximum tolerated dose found in a phase I
study with the same schedule in pretreated patients (Sessa et al,
1995). Dose escalation to 175 mg m-2 was allowed from course 3
(see below). Treatment was scheduled for every 3 weeks, with
appropriate modifications when necessary (see below), to a
maximum of six courses in the absence of disease progression,
unacceptable toxicity or patient refusal.
All patients were treated as outpatients, except for days 1 and 2
of the first two courses, when they were hospitalized to allow
pharmacokinetic sampling. Etoposide phosphate and etoposide
were administered orally in capsule formulations containing
50 mg molar equivalent of etoposide and 50 mg etoposide respec-
tively (both provided by Bristol-Myers Squibb, Wallingford, CT,
USA). The daily dose was rounded to the nearest 50 mg, as only
whole capsules were administered. Patients received the study
drug as a single daily dose in the morning after an overnight fast.
On day 1 (day of pharmacokinetic sampling) of the first two
courses, food and concomitant medication were withheld for 2 h
after drug administration to avoid interference with absorption.
The study drug was administered with at least 150 ml of water in
an upright position and patients were encouraged to walk around
afterwards. To allow longer sampling after the first dose, on day 2
of the first and second courses the study drug was readministered
in the evening after the last pharmacokinetic sample.
Pharmacokinetic sample collection and handling
Blood samples (8 ml) for pharmacokinetic analysis were collected
just before and over 33 h after the first dose (day 1) ofthe first and
second course. The samples were collected in Vacutainer tubes
(Becton Dickinson Vacutainer Systems Europe, Meylan, France)
containing ethylenediamine tetraacetic acid tripotassium salt
(K3EDTA). The sample collection times were 0 (pre-dose), 10, 20,
30, and 45 min and 1, 1.5, 2, 2.5, 3, 4, 6, 8, 11, 14, and 33 h.
Samples were obtained through an intravenous catheter in the
forearm. After collection, the tubes were gently inverted a few
times to ensure thorough mixing and immediately placed on ice.
The samples were centrifuged within 1 h after collection at 1500g
for 5 min at 4°C. Plasma was separated and transferred into
labelled polypropylene tubes and stored frozen at -20°C until
analysis for etoposide and etoposide phosphate.
Assay of study samples
The plasma concentrations of etoposide phosphate and etoposide
were determined with high-performance liquid chromatography
(HPLC) assay methods. For the determination of etoposide in
plasma samples, a chloroform extraction at neutral pH was
used, with teniposide (Bristol-Myers Squibb; lot no. 79F117) as
internal standard. The plasma samples were thawed and, to 1 ml,
50 pl of a stock 200 mg 1-1 teniposide solution was added before
extraction with 2 ml ofchloroform (Merck, Darmstadt, Germany).
Subsequently, the aqueous layer was removed and the organic
layer was washed twice with 1 ml of 0.01 M phosphate buffer
(pH 7.3). The organic layer was dried under nitrogen gas at
ambient temperature and the residue was reconstituted in 50 p1 of
the mobile phase solution. Then 25 gl was injected onto a
Lichrosorb RP-18 5-pm HPLC column, 250 x 4.0 mm ID. The
mobile phase was a methanol plus water (= 50 ml + 49 ml) solu-
tion (at pH 3.3 with acetic acid) at a flow rate of 1.3 ml min-m. An
UV-spectrophotometer (Spectroflow 757, ABI Analytical, Kratos
Division) at 280 nm was used as detector. The concentrations were
calculated on a calibration curve using spiked pool human plasma
that had been handled the same way at the same time. The lower
limit ofquantitation was 0.2 mg 1-1 etoposide. Extraction ofetopo-
side was 96.0 ± 8.2%. The calibration curves were linear over the
range 0.2-10 mg 1-' with a correlation coefficient (r) . 0.99. For
concentrations exceeding the upper limit of the calibration curve,
determination was performed after threefold dilution with blank
plasma. The calibration curve with this dilution step was linear
over a concentration range of0.2-15 mg 1-1 etoposide; coefficient
ofvariation (CV) = 4.8% at 7.9 mg 1-1.
For determination of plasma etoposide phosphate concentra-
tions a solid-phase extraction with metoprolol tartrate as internal
standard was used. To 0.6 ml of plasma, 50 pl of a stock meto-
prolol solution (8 mg 1-') plus 0.55 ml of sodium phosphate buffer
(pH 7.0) were added. One millilitre of the resulting solution was
transferred to a conditionedC,8 column (Bakerbond Spe, JT Baker,
Deventer, The Netherlands) and washed with 3 ml of demineral-
ized water followed by 2 ml of diethylether (Merck). The etopo-
side phosphate was eluted with 2 ml of 1% triethylamine in
methanol under vacuum. The elute was evaporated under nitrogen
gas at 50°C and reconstituted with 200 pl ofwater containing 10%
acetonitrile (Rathburn Chemicals, Walkerburn, UK). Then a 50-gl
sample was injected onto a Bakerbond phenylethyl 5-pm HPLC
column, 250 x 4.6 mm ID (JT Baker). As mobile phase a mixture
of water (850 ml), acetonitrile (150 ml), tetramethyl ammonium
hydroxide (1.8 g) and diammonium hydrogen phosphate (2.64 g),
atpH 3.0 with phosphoric acid 8.5%, was used at a flow rate of 1.4
ml min-'. Detection was performed with a fluorescence detector,
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aOne patient also received immunotherapy and four also radiotherapy.
with excitation at 288 nm and emission at 320 nm (Hitachi F-
1050). The lower limit of quantitation was 0.01 mg 1-' etoposide
phosphate. Extraction of etoposide phosphate was 84.5 ± 4.9%.
The calibration curves were linear over the range 0.01-1 mg 1-1
etoposide phosphate with r . 0.99.
For both etoposide and etoposide phosphate the minimum
criteria foraccepting analytical runs were an accuracy ofpredicted
quality control (QC) samples within 15% of the nominal value,
and abetween- and within-day precision ofthe QC samples within
15% relative standard deviation.
Pharmacokinetic analysis
The plasma concentration versus time data were analysed with a
non-compartmental method (Riegelman and Collier, 1980; Gibaldi
and Perrier, 1982). The peak plasma concentration (Cmax), and the
time to reach peak concentration (Tm) were recorded directly
from experimental observations. Using no weighting factor, the
terminal log-linear phase of the plasma concentration vs time
curve was identified by least-squares linear regression of at least
three data points that results in a minimum mean square error. The
half-life of the terminal log-linear phase (T,,2) was calculated as
0.693/K, where Kis the absolute value ofthe slope ofthe terminal
log-linear phase. The area under the plasma concentration vs time
curve from zero to infinity (AUCiff) was determined by summing
the areas from time zero to the time of last measured concentra-
tion, calculated by using conventional trapezoidal and log-
trapezoidal methods, and the extrapolated area. The extrapolated
area was determined by dividing the final concentration by the
slope ofthe terminal log-linear phase.
Toxicity evaluation and dose modifications
Complete blood counts and differentials were repeated twice
weekly during the first two courses and weekly in subsequent
courses. Clinical toxicity was evaluated at each patient visit.
Toxicities were reported using the WHO grading (WHO, 1979). In
the absence of any haematological toxicity more than grade II
during the first two courses, the dose was escalated to 175 mg m-2
once daily for 5 consecutive days from course 3. In the occurrence
ofgrade III or IV myelosuppression dose was reduced by 25% for
subsequent courses. Retreatment prerequisites were leucocytes
2 3.0 x 103 l-'l and platelets 2 100 x 103 1l'; otherwise the treat-
ment was postponed by 1-week intervals.
Patient 9
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Figure 1 Typical etoposide plasma concentration curves after oral etoposide (O-O) and oral etoposide phosphate (@-*) in two patients. The numbers of
the patients correspond with Figure 3. In patient 9, both plasma concentrations 33 h after administration were below the lower limit of quantitation (< 0.2 mg 1-')
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Figure 2 AUC., values for etoposide plasma concentration after oral
etoposide (1I) and oral etoposide phosphate (U) in all patients. Patients 16
and 17 received only one course
Efficacy criteria
Tumour measurements were performed with the appropriate
imaging procedures before start of therapy and after every two
courses. A complete response was defined as complete disappear-
ance of all measurable tumours and of all signs and symptoms of
disease for at least 4 weeks. A partial response was defined as a
decrease of at least 50% in the sum of the products of the two
largest perpendicular diameters of all measurable tumours, main-
tained for at least 4 weeks. Progressive disease was defined as an
increase of at least 25% in the sum of the products of the two
largest perpendicular diameters of all measurable tumours, or the
appearance of disease in any new localization. Patients not
fulfilling criteria for partial response or progression were
considered to have stable disease.
Statistical analyses
Descriptive summary statistics were calculated for the pharmaco-
kinetic parameters of etoposide following oral etoposide phos-
phate and following oral etoposide. Variability of the AUCinf was
expressed as the coefficient of variation (CV) for the mean.
Comparisons between pharmacokinetic parameters of the first vs
the second course were based on the median values, with 95%
confidence intervals (CI), because of non-normal distribution of
the data. The Wilcoxon test for paired data was used to test for
difference. The Spearman rank correlation test was used to test for
correlation between etoposide AUCinf and per cent decrease in
leucocyte or neutrophil counts. All statistical tests were performed
two-sided at the 5% significance level.
RESULTS
Seventeen patients received a total of 59 treatment courses. Patient
characteristics at start of treatment are shown in Table 1. Although
serum creatinine was < 120 ,umol 1-1 in all patients, estimated
creatinine clearance was < 70 ml min-' in five (lowest value
59 ml min-'). Hypoalbuminaemia was found in two patients (27 g 1-l
and 33 g 1-1). Two patients received only one course as one patient
had tumour progression and the other refused further treatment.
Seven patients received two courses, and in one ofthese total dose
of the second course was 25% reduced because of grade IV
neutropenia following course 1 (this dose reduction was applied
such that the dose on day 1 remained 125 mg m-2). One patient
received three, one patient four and six patients six courses.
Etoposide phosphate dose was escalated to 175 mg m-2 in seven of
the eight patients that received more than two courses. In one of
these patients the dose had to be reduced to 125 mg m-2 again after
one course because of grade III leucopenia. Generally sufficient
haematological recovery was possible within the 3-weekly schedule
as only five courses (in three patients) had to be delayed for 1 week
because of an inadequate leucocyte count. Twelve patients were
evaluable for response after two courses; the remaining patients
who received two or more courses had either non-measurable
disease (one patient) or were not evaluable because of previous
radiotherapy to the tumourregions (two patients).
Thirteen patients received concomitant medication during the
pharmacokinetic part of the study, which was withheld according
to the protocol for 2 h after study drug administration. Analgesics
included oral morphine in five and codeine in one patient, which
drugs were administered atthe same dose during both courses with
pharmacokinetic sampling. In three patients lactulose syrup was
prescribed for constipation prophylaxis and this was withheld till
after pharmacokinetic sampling. Seven patients used benzodi-
azepines and otherdrugs used were acetaminophen, indomethacin,
captopril, triamterene-hydrochlorothiazide, digoxin, dipyri-
madole, acenocoumarol, prednisolone and cinnarizine. No
antacids, acid secretion inhibitors or antiemetics were used at the
time ofpharmacokinetic sampling.
Table 2 Pharmacokinetic parameters of etoposide following oral administration of 125 mg m-2 (in etoposide molar equivalent)
etoposide phosphate or etoposide in 15 patients
Pharmacokinetic Etoposide phosphate (A) Etoposide (B) Within-subject difference (A-B)
parameter
Median 95% Cl Median 95% Cl Median 95% Cl
AUCinf (mg l-l h) 77.7 61.3-100.5 62.0 52.2-76.9 9.9 0.1-32.8
aAUC,nfa (mg 1- h) 80.0 65.3-101.7 63.5 53.4-80.7 10.7 0.2-32.5
Cmax (mg l-1) 11.1 8.5-14.0 9.9 7.5-13.2 0.85 -0.785-3.061
T,2 (h) 7.7 6.4-8.7 6.9 5.6-8.5 0.6 -0.8-2.18
TM. (h) 1.33 1.00-1.69 1.23 0.76-1.53 0.07 -0.25-0.41
aAUCinf adjusted for actual dose per M2.aAUCinf =AUCin, x (125 x body surface area in m2 per actual dose in mg).



































Figure 3 AUCint values for etoposide plasma concentration after oral
etoposide phosphate (y-axis) compared with AUCj, after oral etoposide
(x-axis). Included are data from patients 1-15 in Figure 2. The line of identity
and lines representing 50% difference compared withAUCin, after oral
etoposide are shown. The median ratio of the AUC,,n after etoposide
phosphate vsAUCGnf after etoposide (y/x) was 121% (95% Cl 101-161%)
Pharmacokinetics
Fifteen patientsreceived at least two courses withpharmacokinetic
sampling. Eight of these patients received etoposide on day 1 of
the first course and the other seven on day 1 ofthe second course.
Two patients had pharmacokinetic sampling only during one
course and were excluded from the comparisons between pharma-
cokinetic parameters.
The etoposide plasma concentration vs time curves showed for
both drugs a similar profile in most patients (curves of two repre-
sentative patients shown in Figure 1).
TheAUCinf ofetoposide after either drug is depicted in Figure 2
for all patients in increasing order ofAUCinf after etoposide phos-
phate. The pharmacokinetic parameters of etoposide after oral
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Figure 4 Per cent decrease in leucocyte counts during the first course
compared with etoposide AUCAUCin, after oral etoposide phosphate
(r= 0.51, P= 0.04, n = 16)
patients who received both drugs, as summarized in Table 2. A
borderline significantly higher AUCinf of etoposide after oral
etoposide phosphate was found compared with oral etoposide
(P = 0.05). However, the difference inAUCinf was widely variable
within patients, as shown in Figure 3. Also, equally wide inter-
patient variability for AUCinf was observed after either drug.
Variation ofthe mean was 48.4% after etoposide and 42.3% after
etoposide phosphate. No differences were found forthe otherphar-
macokinetic parameters (Table 2). Median Tmax was not different
for the two drugs, indicating fast conversion of the prodrug into
etoposide. No etoposide phosphate was detected in any of the
pharmacokinetic samples from the first five patients, which also
indicated fast conversion (further analysis for etoposide phosphate
was stopped after these negative results).
Because the drug dose was rounded to the nearest 50 mg,
AUCinf was also compared after correction for actual dose per m2
(Table 2). This resulted in similar findings.
Table 3 Haematological toxicity (17 patients)
Courses 1 and 2a Courses 3-6b
WHO grade WHO grade
0 1 11 III IV 0 1 11 III IV
Leucocytes (52 courses evaluable)
Patients 4 5 5 2 1 1 2 4 1
Courses 10 11 7 2 1 5 6 9 1 -
Neutrophils (45 courses evaluable)
Patients 5 4 2 1 3 1 - 2 3 1
Courses 11 8 3 1 3 2 5 7 4 1
Platelets (52 courses evaluable)
Patients 14 1 1 - 1 8 - - - -
Courses 29 1 1 - 1 21 - - - -
aDose 125 mg m-2 day-' x 5; b dose escalated to 175 mg m-2 day x 5 in 7/8 patients.
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Haematological toxicities
Complete blood counts were performed according to the protocol
in 31 out of 32 first and second courses and from 21 out of 27
courses thereafter. Differentials were performed at the same times
in 45 of these 52 courses. Haematological toxicities are summa-
rized in Table 3, with toxicities of the first two courses combined
separately because dose escalation was allowed from course 3.
Grade III or IV leucopenia developed in three patients (18%) and
grade II in five patients (29%) after the first two courses at
125 mg m-2. Two patients who received the maximum six courses
experienced not more than grade I leucopenia despite dose escala-
tion to 175 mg m-2. However, neutropenia grade III or IV devel-
oped after 26% of courses 3-6. Most patients experienced only
grade 0 thrombocytopenia, although grade IV developed in one
patient. Five patients received a total of eight blood transfusions
for symptomatic anaemia (grade II or III).
An association was found between AUCinf of etoposide after
etoposide phosphate and per cent decrease in leucocyte count
(Figure 4). When compared with per cent decrease in neutrophils,
a similar correlation coefficient was found (r = 0.54), but
neutrophil counts were only available for 11 patients and statistical
significance could not be demonstrated. AUCinf was compared
with toxicity of course 1 only to exclude the influence ofprevious
courses on toxicity. The data in Figure 4 show the wide variation
in toxicity of a similar etoposide phosphate dose in different
patients. The highest AUCi,,f after etoposide phosphate
(186.56 mg 1-' h) was found in the only patient with grade IV
leuco- and thrombocytopenia. This patient had a decreased renal
clearance (creatinine clearance 69 ml min-m), which might explain
the high AUCinf but also an increased fraction of unbound etopo-
side due to low serum albumin (33 g 1-1). The unbound fraction of
etoposide in plasma, calculated with Stewart's formula, was 13%
in this patient (Stewart et al, 1990).
Non-haematological toxicities
All patients developed complete or near-complete alopecia, often
already after course 2. Mild nausea and vomiting (grade I or II)
occurred in 15 courses (25%). Vomiting, however, was always
transient and never interfered with drug administration during the
pharmacokinetic part of the study. None of the patients reported
interference ofvomiting with drug administration in the outpatient
situation. Three patients developed grade I mucositis each during
one course and two other patients experienced grade I or II diar-
rhoea during one course. Two patients developed transient, prob-
ably drug related, grade I or II elevation in alanine transaminase
during one course.
Efficacy
Of the 12 patients evaluable for tumour response, four had stable
and eight progressive disease.
DISCUSSION
This study indicates that bioavailability of etoposide administered
by the oral route can be increased when administered in the form
ofthe prodrug etoposide phosphate. However, although the overall
analysis revealed a significant difference in favour of etoposide
phosphate, the median increase of the AUC was only 21%. This
represents an absolute increase in bioavailability of about 10%, as
the bioavailability of oral etoposide at the investigated dose is
about 50% (Slevin et al, 1989b). Increases in AUC of 250% were
seen in few patients and the advantage was marginal from the
clinicalpointofview. A similaroverall effect can be achievedby a
relatively small increase of the oral etoposide dose. More impor-
tant, the high inter-patient variability of systemic exposure to
etoposide was not markedly reduced with administration of the
prodrug instead oforal etoposide. This was also illustrated by the
wide range of AUC values after either drug (see Figure 2).
However, it is questionable if the pharmacokinetic variability can
be much improved by improving etoposide bioavailability,
because after intravenous administration of an etoposide dose
resulting in comparable AUC values, still 25% variability was
observed (Chabot et al, 1996).
The number of patients included in this study was relatively
small, but the pharmacokinetic values for etoposide after oral
etoposide phosphate are in concordance with those reported by
other investigators. AUC was compatible with the values reported
in a study that investigated pharmacokinetics of etoposide after
oral and intravenous etoposide phosphate over a wide dose range
of 50-220 mg m-2 (Sessa et al, 1995). In another recent phase I
study, which compared oral etoposide phosphate to intravenous
etoposide, similarpharmacokinetic values were obtained after oral
etoposide phosphate and the investigators reported a similar
increase ofbioavailability in a comparison with literature data on
oral etoposide (Chabot et al, 1996). However, only in the present
study directcomparisons were made between both drugs after oral
administration.
It was reported thatetoposide phosphate plasma level decreased
rapidly after intravenous administration (T,12 = 0.08 h), probably
because ofplasmaphosphatases (Budman et al, 1994; Fields et al,
1995; Sessa et al, 1995). Ourfinding thatetoposidephosphate was
never detectable in plasma after oral administration was also
observed by other investigators (Sessa et al, 1995), and therefore
not unexpected. This does not exclude the possibility that
phosphatases present in the intestinal lumen convert a substantial
amount ofprodrug to etoposide even before absorption.
Although this study does not enable a direct comparison of the
toxicities of both drugs when given orally, at the given dose and
schedule side-effects oforaletoposidephosphate werecomparable
to those oforal etoposide and in particulargastrointestinal toxicity
of the prodrug was of the same magnitude as seen with oral
etoposide (nausea and vomiting grade I-II in only a minority of
the patients [Hainsworth and Greco, 1995]). Also, no differences
in toxic side-effects were found in a comparative study of both
drugs given intravenously (Hainsworth et al, 1995).
Our results showed that a dose of 125-175 mg m-2 for 5 days
every 3 weeks is near the maximum tolerable dose for previously
treated patients. The treatment-free interval (16 days) was gener-
ally sufficient for haematological recovery. In the present study
AUCinf correlated with the per cent decrease in the leucocyte
count, as reported by others (Fields et al, 1995; Sessa et al, 1995).
However, the relatively low correlation coefficient indicates that
the variability of the haematological toxicity after oral etoposide
phosphate or etoposide is largely determined by factors other than
dose or AUC. It is known from other studies that severe haemato-
logical toxicity can occur in elderly patients, in those with
decreased renal function and when there is an increased unbound
plasma etoposide fraction in patients with low albumin levels
(Stewart et al, 1991; Pfliger et al, 1993; Liu et al, 1995). In our
study, the only patient with grade IV haematological toxicity had
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mildly impaired renal function and an increased fraction of
unbound etoposide in plasma. The percentage unbound etoposide
was 13%, whereas a mean of 5% was reported in subjects with
normal serum bilirubin and albumin levels (Stewart et al, 1989).
The present study was not designed to prove the efficacy oforal
etoposide phosphate at the chosen dose and schedule. No objective
responses were seen, but the patients in the study were often
heavily pretreated and only 12 were evaluable fortumourresponse.
Interest in the oral administration of etoposide phosphate was
raised because oral etoposide showed promising results in second-
line treatment of several malignancies (Hainsworth and Greco,
1995), but its incomplete and variable bioavailability is an impor-
tant drawback. This is a disadvantage that etoposide shares with
other commonly used oral anti-cancer drugs. Similar variation in
bioavailability has been reported for melphalan and cyclophos-
phamide, whereas bioavailability oforal mercaptopurine was only
16% (Bosanquet and Gilby, 1982; Zimm et al, 1983; Wagner and
Fenneberg, 1984). Improving the pharmacological properties of
oral anti-cancer drugs is therefore an important goal in the devel-
opment of these drugs. Oral administration of the prodrug etopo-
side phosphate instead of etoposide did not result in a clinically
relevant improvement as despite a small significant increase in
bioavailability, variability appeared to be unaltered.
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